Sun Pharmaceutical on Friday announced that one of its subsidiaries has been granted US FDA's final approval “for its abbreviated new drug application (ANDA) for the generic version” of Novartis’ Gleevec, a drug for chronic myeloid leukemia (a rare form of blood cancer). Following the announcement, Sun Pharmaceutical's shares surged by over 5.5% during intraday trading.